User Guide
Why can I only view 3 results?
You can also view all results when you are connected from the network of member institutions only. For non-member institutions, we are opening a 1-month free trial version if institution officials apply.
So many results that aren't mine?
References in many bibliographies are sometimes referred to as "Surname, I", so the citations of academics whose Surname and initials are the same may occasionally interfere. This problem is often the case with citation indexes all over the world.
How can I see only citations to my article?
After searching the name of your article, you can see the references to the article you selected as soon as you click on the details section.
Institutional References Quartile Statistics FAQ User Guide Contact us
Institutional Application Application for Journals
Türkçe English
 ASOS INDEKS
 Views 7
Menu
Mendeley
Endnote
Neutropenic Fever, Skin and Eye Toxicities Develops During Docetaxel Treatment in Metastatic Prostate Cancer: A Case Report
2017
Journal:  
Bulletin of Urooncology
Author:  
DOI:  
10.4274/uob.908
Abstract:

Prostate cancer is one of the most common tumors in men. Docetaxel and prednisone treatment are accepted as standard therapy in castration-resistant prostate cancer patients. Docetaxel is a chemotherapeutic drug of the taxane group that inhibits depolymerization of tubulin and has an antitumoral activity through stabilization of microtubules. It has also been reported that docetaxel therapy lead to cutaneous and eye side effects besides systemic side effects. Skin and eye toxicities are more common with weekly docetaxel treatment than three-week regimens. We would like to present our case of neutropenia, eye and skin toxicities with docetaxel chemotherapy treatment which is commonly used in metastatic prostate cancer patients.

Keywords:

Citation Owners
Information: There is no ciation to this publication.
Similar Articles
1. New treatment options for the castration resistant prostate cancer: Cabazitaxel and Spileucel-T
2013


  Details
 Download PDF
2. Are there any treatment option for metastatic prostate cancer refractory to docetaksel?
2011


  Details
 Download PDF
3. ‘Nanotechnology Applications’ in the Treatment of Prostate Cancer
2015


  Details
 Download PDF
4. In which fields intermittent androgen deprivation therapy can be used in 2014?
2014


  Details
 Download PDF
5. New treatment stragies in metastatic castration resistant prostate cancer: Re-Docetaxel, Abiraterone asetate, Cabazitaxel, MDV 3100
2012


  Details
 Download PDF
6. New treatment options for the castration resistant prostate cancer targeting the androgen synthesis and androgen receptor
2013


  Details
 Download PDF
Bulletin of Urooncology

Field :   Sağlık Bilimleri

Journal Type :   Uluslararası

Metrics
Article : 112
Cite : 2
2023 Impact : 0.012
Details
Bulletin of Urooncology